693820-77-8Relevant articles and documents
Quinazolinone derivatives as orally available ghrelin receptor antagonists for the treatment of diabetes and obesity
Rudolph, Joachim,Esler, William P.,O'Connor, Stephen,Coish, Philip D. G.,Wickens, Philip L.,Brands, Michael,Bierer, Donald E.,Bloomquist, Brian T.,Bondar, Georgiy,Chen, Libing,Chuang, Chih-Yuan,Claus, Thomas H.,Fathi, Zahra,Fu, Wenlang,Khire, Uday R.,Kristie, James A.,Liu, Xiao-Gao,Lowe, Derek B.,McClure, Andrea C.,Michels, Martin,Ortiz, Astrid A.,Ramsden, Philip D.,Schoenleber, Robert W.,Shelekhin, Tatiana E.,Vakalopoulos, Alexandras,Tang, Weifeng,Wang, Lei,Yi, Lin,Gardell, Stephen J.,Livingston, James N.,Sweet, Laurel J.,Bullock, William H.
, p. 5202 - 5216 (2008/03/12)
The peptide hormone ghrelin is the endogenous ligand for the type 1a growth hormone secretagogue receptor (GHS-R1a) and the only currently known circulating appetite stimulant. GHS-R1a antagonism has therefore been proposed as a potential approach for obe